ATAI announced completion of dosing in the Phase IIb Elumina study of VLS-01 for treatment-resistant depression. Top-line efficacy and safety data are expected in Q4 2026, providing a clear upcoming catalyst while offering limited near-term financial impact today.
ATAI announced completion of dosing in the Phase IIb Elumina study of VLS-01 for treatment-resistant depression. Top-line efficacy and safety data are expected in Q4 2026, providing a clear upcoming catalyst while offering limited near-term financial impact today.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
